课题基金 / 基金详情

A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF

A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF
IV 期、前瞻性、随机、开放标签的疗效评估
批准号：
7951540
负责人：
Judith S. Currier
金额：
$1.62万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-04-01 至 2009-11-30
来源：
https://reporter.nih.gov/project-details/7951540
关键词：
AreaClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantHIV-1IndividualInstitutionPhaseRandomizedResearchResearch PersonnelResourcesSourceTreatment ProtocolsUnited States National Institutes of Healthefficacy evaluationopen labelprospective

项目摘要

项目成果

Judith S. Currier的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Objective To demonstrate the non-inferiority of a once-daily PI- and a once-daily NNRTI-containing regimen as compared with standard twice-daily ARV therapy for the initial treatment of individuals infected with HIV-1 from diverse areas of the world.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
UCLA-CDU CFAR
海外基金